Is There a Place for Medicinal Cannabis in Treating Patients with Sleep Disorders? What We Know so Far

被引:10
|
作者
Maddison, Kathleen J. [1 ,2 ]
Kosky, Christopher [1 ]
Walsh, Jennifer H. [1 ,2 ]
机构
[1] Sir Charles Gairdner Hosp, West Australian Sleep Disorders Res Inst, Dept Pulm Physiol & Sleep Med, Perth, WA, Australia
[2] Univ Western Australia, Ctr Sleep Sci, Perth, WA, Australia
来源
NATURE AND SCIENCE OF SLEEP | 2022年 / 14卷
关键词
cannabinoid; insomnia; obstructive sleep apnea; restless legs syndrome; REM behavior disorder; nightmare disorder; BEHAVIOR DISORDER; REM-SLEEP; ADMINISTERED DELTA-9-TETRAHYDROCANNABINOL; NIGHTMARE DISORDER; AMERICAN ACADEMY; PRACTICE GUIDE; DOUBLE-BLIND; CHRONIC PAIN; MARIJUANA; EFFICACY;
D O I
10.2147/NSS.S340949
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The legalization of cannabis for medicinal, and in some countries, recreational, purposes in addition to growth in the cannabis industry has meant that cannabis use and interest in the area has increased rapidly over the past 20 years. Treatment of poor sleep and sleep disorders are two of the most common reasons for the current use of medicinal cannabis. However, evidence for the role of medical cannabis in the treatment of sleep disorders has not been clearly established, thus making it challenging for clinicians to make evidence-based decisions regarding efficacy and safety. This narrative review summarizes the highest quality clinical evidence currently available in relation to the use of medicinal cannabis for the treatment of sleep disorders including insomnia, obstructive sleep apnea, restless legs syndrome, rapid eye movement sleep behavior disorder, nightmare disorder and narcolepsy. A summary of the effect of cannabis on sleep quality and architecture is also presented. Currently, there is insufficient evidence to support the routine use of medicinal cannabis as an effective and safe treatment option for any sleep disorder. Nevertheless, emerging evidence is promising and warrants further investigation using standardized cannabinoid products and validated quantitative measurement techniques.
引用
收藏
页码:957 / 968
页数:12
相关论文
共 50 条
  • [1] Thirst in patients on chronic hemodialysis: What do we know so far?
    Bossola, Maurizio
    Calvani, Riccardo
    Marzetti, Emanuele
    Picca, Anna
    Antocicco, Emanuela
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2020, 52 (04) : 697 - 711
  • [2] Ketogenic Diet and Epilepsy: What We Know So Far
    Meira, Isabella D'Andrea
    Romao, Tayla Taynan
    Pires do Prado, Henrique Jannuzzelli
    Kruger, Lia Theophilo
    Paiva Pires, Maria Elisa
    da Conceicao, Priscila Oliveira
    FRONTIERS IN NEUROSCIENCE, 2019, 13
  • [3] Scalp Seborrheic Dermatitis: What We Know So Far
    Leroy, Anne Kelly
    de Almeida, Rita Fernanda Cortez
    Obadia, Daniel Lago
    Frattini, Sidney
    Melo, Daniel Fernandes
    SKIN APPENDAGE DISORDERS, 2023, 9 (03) : 160 - 164
  • [4] What Do We Know About Medical Cannabis in Neurological Disorders and What Are the Next Steps?
    Lacroix, Clemence
    Alleman-Brimault, Isabelle
    Zalta, Arnaud
    Rouby, Frank
    Casse-Perrot, Catherine
    Jouve, Elisabeth
    Attolini, Laurence
    Guilhaumou, Romain
    Micallef, Joelle
    Blin, Olivier
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [5] What We Know So Far About ECG for Pancreatic Pseudocysts
    Kluszczyk, Paulina
    Jablonska, Beata
    Serafin, Michal
    Tobiasz, Aleksandra
    Kowalczyk, Tomasz
    Maslanka, Sebastian
    Chapula, Mateusz
    Wosiewicz, Piotr
    Mrowiec, Slawomir
    LIFE-BASEL, 2024, 14 (11):
  • [6] Sleep, Sleep Disorders, and Mild Traumatic Brain Injury. What We Know and What We Need to Know: Findings from a National Working Group
    Wickwire, Emerson M.
    Williams, Scott G.
    Roth, Thomas
    Capaldi, Vincent F.
    Jaffe, Michael
    Moline, Margaret
    Motamedi, Gholam K.
    Morgan, Gregory W.
    Mysliwiec, Vincent
    Germain, Anne
    Pazdan, Renee M.
    Ferziger, Reuven
    Balkin, Thomas J.
    MacDonald, Margaret E.
    Macek, Thomas A.
    Yochelson, Michael R.
    Scharf, Steven M.
    Lettieri, Christopher J.
    NEUROTHERAPEUTICS, 2016, 13 (02) : 403 - 417
  • [7] Diets for inflammatory bowel disease: What do we know so far?
    Serrano-Moreno, Clara
    Brox-Torrecilla, Noemi
    Arhip, Loredana
    Romero, Inmaculada
    Morales, Angela
    Luisa Carrascal, M.
    Cuerda, Cristina
    Motilla, Marta
    Camblor, Miguel
    Velasco, Cristina
    Breton, Irene
    EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2022, 76 (09) : 1222 - 1233
  • [8] Cognitive Impairment in Parkinson's Disease: What We Know so Far
    Painous, Celia
    Marti, Maria J.
    RESEARCH AND REVIEWS IN PARKINSONISM, 2020, 10 : 7 - 17
  • [9] COVID-19 vaccines: what do we know so far?
    Dhillon, Paraminder
    Altmann, Daniel
    Male, Victoria
    FEBS JOURNAL, 2021, 288 (17) : 4996 - 5009
  • [10] Pirfenidone use in fibrotic diseases: What do we know so far?
    Torre, Aldo
    David Martinez-Sanchez, Froylan
    Mercedes Narvaez-Chavez, Sofia
    Ariel Herrera-Islas, Mariana
    Alberto Aguilar-Salinas, Carlos
    Cordova-Gallardo, Jacqueline
    IMMUNITY INFLAMMATION AND DISEASE, 2024, 12 (07)